The ADAPT HR+/Her2- Study is a WSG sponsored study, which involves the dynamic testing of HR+/Her2- breast cancer patients. Palleos delivers a full-service management including Data Management, Project Management, Regulatory Affairs, Monitoring, IT infrastructure, site management, and financial management in Germany. For scientific details see the Sponsor’s homepage.
- 4000 Patients, 80 Sites [LPI: Q2 2015]
- Indication: Oncology
- Sponsor: Westdeutsche Studiengruppe
- CRO | Acting as preferred provider for the WSG | Full-service